Blue Lotus China New Economy Research, Blue Lotus Research Institute

Eric Wen

Blue Lotus China New Economy Research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>300750 SZ: CATL’s result in 4Q23 showed clear impact of price war (/)</li>
<li>NIO: Huawei AITO M9 ranks first in weekly sales among SUVs above Rmb500K(/)</li>
<li>BGNE: BeiGene’s Tislelizumab approved by FDA for esophageal squamous cancer, but with little revenue potential (/)</li>
</ul>


300750 SZ: CATL’s result in 4Q23 showed clear impact of price war (/)
NIO: Huawei AITO M9 ranks first in weekly sales among SUVs above Rmb500K(/)
BGNE: BeiGene’s Tislelizumab approved by FDA for esophageal squamous cancer, but with little revenue potential (/)


[Blue Lotus Daily]：300750 SZ/NIO/BGNE/1810 HK

Articles from Caixin Global, Caixin Global

Caixin Global

Articles from Caixin Global

Caixin is a media group dedicated to providing financial and business news through periodicals, online content, mobile apps, conferences, books and TV/video programs. Caixin aims to blaze a trail that helps traditional media prosper in the new media age through integrated multimedia platforms.

News from Caixin

Cross Asset Strategy

<ul><li>Travel / In Depth: China targets payments problem to win over foreigners</li><li>Corruption /: China’s former counterterrorism official caught in graft probe</li><li>Insurers /: Risk now determines how strictly China’s life insurers get regulated</li></ul>

Travel / In Depth: China targets payments problem to win over foreignersCorruption /: China’s former counterterrorism official caught in graft probeInsurers /: Risk now determines how strictly China’s life insurers get regulated

CX Daily: China Targets Payments Problem To Win Over Foreigners 

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for holding position as of March 15th.</li>
<li>We estimate the weekly inflows to be US$5,038.2 million, led by industrials, consumer discretionary, consumer staples sectors.</li>
<li>We highlight flows for CATL, Wuliangye, China Tourism, Moutai, Midea.</li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for holding position as of March 15th.
We estimate the weekly inflows to be US$5,038.2 million, led by industrials, consumer discretionary, consumer staples sectors.
We highlight flows for CATL, Wuliangye, China Tourism, Moutai, Midea.


Northbound Flows (Mar 15th): $5bn of Inflows Last Week

Pan-Asia Index Flows & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Pan-Asia Index Flows & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

Ningbo Ronbay New Energy Techn / Event-Driven

<ul>
<li>STAR 50 Index is a tech-focused, blue-chip index in Mainland China which tracks the top 50 largest and most liquid names in the STAR market of the Shanghai Stock Exchange.</li>
<li>In this insight, we take a look at our expectations for potential ADDs and DELs for the STAR 50 index during the June 2024 index rebal event.</li>
<li>I currently expect three changes for the STAR 50 index in June 2024 but there are some questions marks over the names leading the race to become ADDs.</li>
</ul>


STAR 50 Index is a tech-focused, blue-chip index in Mainland China which tracks the top 50 largest and most liquid names in the STAR market of the Shanghai Stock Exchange.
In this insight, we take a look at our expectations for potential ADDs and DELs for the STAR 50 index during the June 2024 index rebal event.
I currently expect three changes for the STAR 50 index in June 2024 but there are some questions marks over the names leading the race to become ADDs.


Quiddity Leaderboard STAR 50 Jun 24: 3 Changes Likely But Some Question Marks Over Certain Names

<ul>
<li>BGNE: BeiGene's Brukinsa received fifth indication from FDA but might be the last driver (+)</li>
<li>LI/XPEV: Li MEGA delivered 413 units in three days after its launch, in line with our predictions, better than market predictions(/)</li>
<li>300750 CH：Samsung SDI announces production of large cylindrical batteries in 2025 and mass production of solid-state batteries in 2027（-）</li>
</ul>


BGNE: BeiGene's Brukinsa received fifth indication from FDA but might be the last driver (+)
LI/XPEV: Li MEGA delivered 413 units in three days after its launch, in line with our predictions, better than market predictions(/)
300750 CH：Samsung SDI announces production of large cylindrical batteries in 2025 and mass production of solid-state batteries in 2027（-）


[Blue Lotus Daily]：BGNE/LI/XPEV/300750 CH

China

Contemporary Amperex Technology Co., Limited. operates as a battery products manufacturing company. The Company produces and sells power battery materials, energy storage batteries energy storage battery cells, systems, and other products. Contemporary Amperex Technology also provides batteries recycling services.

Contemporary Amperex Technology (CATL) (300750 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Contemporary Amperex Technology (CATL) (300750 CH)

[Blue Lotus Daily]：300750 SZ/NIO/BGNE/1810 HK

CATL's 4Q23 results impacted by price war, NIO's Huawei AITO M9 SUV leads in sales over Rmb500K, BeiGene's Tislelizumab FDA approval for...

Blue Lotus Research Institute

CX Daily: China Targets Payments Problem To Win Over Foreigners

Travel / In Depth: China targets payments problem to win over foreigners Step by step, China has been encouraging more foreigners to enter the...

Caixin Global

Northbound Flows (Mar 15th): $5bn of Inflows Last Week

We analyzed northbound Shanghai/Shenzhen connect flows in the past week and highlight flows for CATL, Wuliangye, China Tourism, Moutai, Midea, Wuxi...

Ke Yan, CFA, FRM

Quiddity Leaderboard STAR 50 Jun 24: 3 Changes Likely But Some Question Marks Over Certain Names

The three expected ADDs could see US$543mn index buying and the three expected DELs could see US$509mn index selling. The top two expected DELs are...

Janaghan Jeyakumar, CFA

[Blue Lotus Daily]：BGNE/LI/XPEV/300750 CH

BGNE's Brukinsa gains fifth FDA indication but future growth uncertain; Li MEGA exceeds expectations; Samsung SDI plans battery production in 2025...

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

[Blue Lotus Daily]：300750 SZ/NIO/BGNE/1810 HK

​CATL's 4Q23 results impacted by price war, NIO's Huawei AITO M9 SUV leads in sales over Rmb500K, BeiGene's Tislelizumab FDA approval for...

Blue Lotus Research Institute

CX Daily: China Targets Payments Problem To Win Over Foreigners

Travel / In Depth: China targets payments problem to win over foreigners Step by step, China has been encouraging more foreigners to enter the...

Caixin Global

Northbound Flows (Mar 15th): $5bn of Inflows Last Week

We analyzed northbound Shanghai/Shenzhen connect flows in the past week and highlight flows for CATL, Wuliangye, China Tourism, Moutai, Midea, Wuxi...

Ke Yan, CFA, FRM

Quiddity Leaderboard STAR 50 Jun 24: 3 Changes Likely But Some Question Marks Over Certain Names

The three expected ADDs could see US$543mn index buying and the three expected DELs could see US$509mn index selling. The top two expected DELs are...

Janaghan Jeyakumar, CFA

[Blue Lotus Daily]：BGNE/LI/XPEV/300750 CH

​BGNE's Brukinsa gains fifth FDA indication but future growth uncertain; Li MEGA exceeds expectations; Samsung SDI plans battery production in 2025...

Blue Lotus Research Institute

CATL's 4Q23 results impacted by price war, NIO's Huawei AITO M9 SUV leads in sales over Rmb500K, BeiGene's Tislelizumab FDA approval for...

BGNE's Brukinsa gains fifth FDA indication but future growth uncertain; Li MEGA exceeds expectations; Samsung SDI plans battery production in 2025...